Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. develops and commercializes medical device products for active healing, pain treatment, musculoskeletal care and surgical applications. The company organizes its portfolio around Pain Treatments, Restorative Therapies and Surgical Solutions, including products such as peripheral nerve stimulation devices, bone graft substitutes, ultrasonics, hyaluronic acid injections and ultrasound-based fracture healing therapies.
Recurring Bioventus news covers quarterly and annual results, financial guidance, revenue trends across its product areas and geographic markets, cash flow and margin performance, healthcare conference presentations, portfolio updates and regulatory developments affecting products such as Peripheral Nerve Stimulation offerings.
Bioventus reported Q2 financial results for 2021, achieving net sales of $109.8 million, an increase of 89.3% year-over-year. This includes $97.9 million from legacy operations and $11.9 million from Bioness Inc. acquisition. Despite a net loss of $10.8 million, this reflects an increase of 80.3% year-over-year. Adjusted EBITDA rose to $19.9 million, up 186.5% year-over-year. The company updated its full-year guidance, projecting net sales growth of 26% to 29% and increased total addressable market to $15 billion.
Bioventus Announces Acquisition of Misonix
Bioventus will acquire Misonix in a cash-and-stock deal valued at approximately $518 million, enhancing its product portfolio and revenue. The transaction involves Misonix stockholders choosing between 1.6839 shares of Bioventus stock or $28.00 in cash. Once completed, the merger aims to accelerate growth opportunities, adding nearly $80 million in revenue for 2021 and generating $20 million in annual cost synergies by year two. The deal awaits regulatory and stockholder approvals, expected to finalize in Q4 2021.
Bioventus Inc. (Nasdaq: BVS) reported preliminary second quarter net sales of $108 million to $110 million, reflecting an impressive 86.2% to 89.7% year-over-year growth. This includes $96.5 million to $98.0 million from legacy operations and $11.5 million to $12.0 million from the recent acquisition of Bioness Inc. Updated full-year guidance anticipates net sales of $405 million to $415 million, marking a 26% to 29% increase. Bioventus also announced its intention to acquire Misonix, expanding its product portfolio in regenerative medicine.
DURHAM, N.C., July 27, 2021 - Bioventus (Nasdaq: BVS) will participate in two virtual conferences: the Canaccord Genuity 41st Annual Growth Conference on August 12 at 3:30 p.m. ET and the Morgan Stanley Virtual Global Healthcare Conference on September 10 at 9:30 a.m. ET. Presentation materials will be available in the investor relations section of the Bioventus website before each event, alongside live audio webcasts and replays accessible for 30 days. Bioventus focuses on clinically proven products for active healing.
Bioventus (Nasdaq: BVS) has appointed Mary Kay Ladone to its Board of Directors, effective July 15, 2021. Ladone, a seasoned executive with over 30 years in global healthcare, will also serve on the Audit and Risk Committee and the Compensation Committee. CEO Ken Reali noted her expertise in strategic planning and investor relations, which will aid Bioventus in its growth strategy focused on new product development and M&A. Ladone previously held positions at Hillrom Holdings and Baxalta, enhancing her credentials in corporate development and investor relations.
Bioventus (BVS) has launched OSTEOAMP SELECT Flowable, an innovative allograft bone graft substitute aimed at enhancing surgical outcomes in spine fusion and other procedures. This product is 100% allograft, free from synthetic carriers, and is designed for smooth handling and effective retention at the grafting site. Available in three sizes, the flowable allograft is terminally sterilized and processed to meet stringent tissue banking standards. The launch follows a limited release in select markets earlier this year, with enthusiastic endorsements from leading spine surgeons highlighting its utility in minimally invasive surgeries.
Bioventus (Nasdaq: BVS) announced a minority investment in Vaporox, a company specializing in diabetic foot ulcer (DFU) wound healing therapy. Vaporox's patented Vaporous Hyperoxia Therapy™ has achieved an 85% healing rate for DFUs typically unresponsive to standard care. This investment aims to serve as a stepping stone to a potential acquisition, enhancing Bioventus's portfolio in the growing DFU treatment market. The terms of the investment remain undisclosed, but it is noted as non-material to Bioventus's finances.
Bioventus (BVS) announced it will release its fiscal Q2 2021 results after market close on August 10, 2021. Management will conduct a conference call at 5:00 PM ET the same day to discuss these results and provide a business update. Interested parties can join the call by dialing the provided numbers. A webcast will also be available on the company’s investor relations website, which will be archived for replay until August 10, 2022. The company focuses on delivering clinically proven products for active healing.
Bioventus Inc. (Nasdaq: BVS) announced that its human placental tissue product, PTP-001, significantly reduced pain and cartilage degeneration in a rat osteoarthritis model during a six-week study. Findings published in Osteoarthritis and Cartilage revealed that PTP-001's efficacy matched corticosteroid treatment. The company sees PTP-001 as a promising candidate for managing osteoarthritis symptoms and potentially modifying the disease. Further research and development plans are in place for PTP-001, aimed at addressing unmet clinical needs.
Bioventus (Nasdaq: BVS) announced its participation in two upcoming virtual conferences: the Canaccord Genuity Virtual Musculoskeletal Conference on May 20 at 8:30 a.m. ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET. Presentation materials will be accessible on the investor relations section of the Bioventus website prior to each event. A live audio webcast and replay links will also be available for 30 days afterward. Bioventus focuses on innovations for active healing, particularly in osteoarthritis and various pain management solutions.